A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers

Charles L. Raison, Robin E. Rutherford, Bobbi J. Woolwine, Chen Shuo, Pamela Schettler, Daniel F. Drake, Ebrahim Haroon, Andrew H. Miller

Research output: Contribution to journalArticlepeer-review

1076 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers'. Together they form a unique fingerprint.

Medicine & Life Sciences

Arts & Humanities